Tenormin is a cardioselective beta-adrenoceptor blocker with preferential effect on beta1-receptors, has no membrane stabilizing effect and SSA. It greatly reduces the maximum pressure in the left ventricle, without significant changing the end-diastolic pressure. Reduces stroke volume, heart rate, myocardial oxygen consumption and cardiac output. Increases systemic vascular resistance. Increases effective renal blood flow, but does not alter glomerular filtration rate even if using is prolonged. Prolongs sinus cycle, the refractory period, slows AV conduction.
Indications for use:
Tachycardia, hypertension, angina pectoris, acute myocardial infarction ( with stable hemodynamics ), sinus, atrial, ventricular and other paroxysmal arrythmia, atrial flutter and atrial fibrillation, cardiac hyperkinetic syndrome, cardiopsychoneurosis by hypertension type, mitral valve prolapse, complex hypertrophic cardiomyopathy's treatment, pheochromocytoma, essential tremor, thyrotoxicosis, migraine (prevention ).
The hypotensive effect for adults is providing by the daily single oral drug's administration of 50-100 mg. Optimum effect is achieved in 1-2 weeks. Further reduction in blood pressure can be achieved by applying in Tenormin combination with other antihypertensive agents. Tenormin combination with diuretics provides high efficiency hypertension's treatment. A positive therapeutic effect for the patients' majority suffering angina pectoris is achieved after daily administration of 100 mg at one dose or two.